Pediatric Intranasal Sumatriptan: Guideline‑Based Recommendations

1. Regulatory Status & Safety of Subcutaneous Formulations

Subcutaneous sumatriptan is not FDA‑approved for children or adolescents and there is insufficient safety and efficacy data for pediatric use; current guideline literature recommends exclusively intranasal formulations for patients < 12 years old. 1
In adults, a 6 mg subcutaneous dose achieves ≈ 59 % complete pain relief at 2 h, but this route has not been adequately studied in children and is associated with higher adverse‑event rates; therefore it should be avoided in the pediatric population. 2

Limit acute intranasal sumatriptan to ≤ 2 days per week to avoid medication‑overuse headache, which can increase headache frequency and lead to daily headaches. 1
If a child requires acute treatment more than twice weekly, initiate preventive therapy promptly rather than increasing the frequency of acute triptan use. 1

Ibuprofen remains the recommended first‑line acute medication for pediatric migraine, dosed according to body weight with early administration; adequate trials of ibuprofen should be completed before escalating to triptans. 1

Intranasal sumatriptan and zolmitriptan are the most effective triptan formulations for adolescents 12–17 years and evidence indicates efficacy extends to children as young as 8 years. (Guideline consensus) 1
The overall evidence base for pediatric triptans is confounded by high placebo response rates, which can mask true drug efficacy in clinical trials. (Guideline observation) 1

Refer to a pediatric headache specialist if intranasal sumatriptan provides insufficient pain relief after 2–3 migraine episodes despite correct use. 1
Refer if the child experiences frequent attacks (≥ 2 days per month) despite optimized acute therapy, indicating a need for preventive treatment. 1

Triptans should not be used in children with any of the following: ischemic heart disease, uncontrolled hypertension, cerebrovascular disease, or basilar/hemiplegic migraine. (Contraindication list) 2
Ensure the child has not taken ergotamine derivatives within the previous 24 hours, as concurrent use is contraindicated due to additive vasoconstrictive effects. 3